Operating
Change in Deferred Revenue
Regeneron Pharmaceuticals Change in Deferred Revenue increased by 3312.9% to $99.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 462.7%, from $17.70M to $99.60M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase indicates strong future demand and cash inflow, while a decrease suggests revenue recognition from previously collected cash.
Detailed definition
This represents the net change in cash received from customers for goods or services that have not yet been delivered or...
Peer comparison
Common in long-term contract businesses like LNG; peers with similar business models often show significant deferred revenue balances.
Metric ID:
change_in_deferred_revenueHistorical Data
16 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$6.40M | -$49.00M | $9.50M | $100.20M | -$35.90M | -$14.50M | $45.30M | $43.00M | $116.90M | $89.10M | $43.00M | $0.00 | $17.70M | -$142.90M | -$3.10M | $99.60M |
| QoQ Change | — | -665.6% | +119.4% | +954.7% | -135.8% | +59.6% | +412.4% | -5.1% | +171.9% | -23.8% | -51.7% | -100.0% | — | -907.3% | +97.8% | >999% |
| YoY Change | — | — | — | — | -477.9% | -114.5% | — | — | +425.6% | +714.5% | -5.1% | -100.0% | -84.9% | -260.4% | — | +462.7% |
Range-$142.90M – $116.90M
CAGR+107.9%
Avg YoY Growth+62.2%
Median YoY Growth-84.9%
Current Streak2 quarters growth
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's change in deferred revenue?
- Regeneron Pharmaceuticals (REGN) reported change in deferred revenue of $99.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's change in deferred revenue changed year-over-year?
- Regeneron Pharmaceuticals's change in deferred revenue increased by 462.7% year-over-year, from $17.70M to $99.60M.
- What does change in deferred revenue mean?
- The net change in payments received from customers for services not yet provided.